EGFR and colorectal carcinoma: This mutation is present on exon 4 and according to NCCN Guidelines for CRC, patients with any known KRAS or NRAS mutation in exon 2, 3, 4 should not be treated with EGFR targeted monoclonal antibodies (cetuximab and panitumumab) (NCCN Guidelines, 2021).